NO331802B1 - Antihypertensiv sammensetning av valsartan og kalsiumblokker - Google Patents
Antihypertensiv sammensetning av valsartan og kalsiumblokker Download PDFInfo
- Publication number
- NO331802B1 NO331802B1 NO20010113A NO20010113A NO331802B1 NO 331802 B1 NO331802 B1 NO 331802B1 NO 20010113 A NO20010113 A NO 20010113A NO 20010113 A NO20010113 A NO 20010113A NO 331802 B1 NO331802 B1 NO 331802B1
- Authority
- NO
- Norway
- Prior art keywords
- hypertension
- pharmaceutically acceptable
- valsartan
- diabetes
- diabetic
- Prior art date
Links
- 239000004072 C09CA03 - Valsartan Substances 0.000 title claims abstract description 29
- 229960004699 valsartan Drugs 0.000 title claims abstract description 29
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title claims abstract 5
- 239000000203 mixture Substances 0.000 title abstract description 13
- 230000003276 anti-hypertensive effect Effects 0.000 title description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title description 2
- 229910052791 calcium Inorganic materials 0.000 title description 2
- 239000011575 calcium Substances 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000000480 calcium channel blocker Substances 0.000 claims abstract description 10
- 239000005557 antagonist Substances 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 239000002552 dosage form Substances 0.000 claims description 18
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 15
- 229960000528 amlodipine Drugs 0.000 claims description 11
- 229960004005 amlodipine besylate Drugs 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 34
- 238000011282 treatment Methods 0.000 abstract description 27
- 206010020772 Hypertension Diseases 0.000 abstract description 24
- 206010019280 Heart failures Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract description 9
- 201000006370 kidney failure Diseases 0.000 abstract description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 8
- 208000001647 Renal Insufficiency Diseases 0.000 abstract description 7
- 208000033679 diabetic kidney disease Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 7
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 208000017169 kidney disease Diseases 0.000 abstract description 6
- 201000001474 proteinuria Diseases 0.000 abstract description 6
- 208000019553 vascular disease Diseases 0.000 abstract description 6
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract description 5
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 230000002861 ventricular Effects 0.000 abstract description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract description 4
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract description 4
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 abstract description 4
- 208000019695 Migraine disease Diseases 0.000 abstract description 4
- 206010039710 Scleroderma Diseases 0.000 abstract description 4
- 206010039808 Secondary aldosteronism Diseases 0.000 abstract description 4
- 230000001154 acute effect Effects 0.000 abstract description 4
- 230000001684 chronic effect Effects 0.000 abstract description 4
- 206010061989 glomerulosclerosis Diseases 0.000 abstract description 4
- 206010020718 hyperplasia Diseases 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 206010027599 migraine Diseases 0.000 abstract description 4
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract description 4
- 230000002792 vascular Effects 0.000 abstract description 4
- 230000001746 atrial effect Effects 0.000 abstract description 3
- 241000124008 Mammalia Species 0.000 abstract description 2
- 206010010356 Congenital anomaly Diseases 0.000 abstract 2
- 210000004072 lung Anatomy 0.000 abstract 2
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 25
- 229940127291 Calcium channel antagonist Drugs 0.000 description 15
- 230000036772 blood pressure Effects 0.000 description 11
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 10
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229960001722 verapamil Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000001631 hypertensive effect Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 102000005862 Angiotensin II Human genes 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 4
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 4
- 208000021642 Muscular disease Diseases 0.000 description 4
- 201000009623 Myopathy Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 229950006323 angiotensin ii Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010042600 Supraventricular arrhythmias Diseases 0.000 description 3
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 239000002220 antihypertensive agent Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 208000002815 pulmonary hypertension Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 2
- 206010003662 Atrial flutter Diseases 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 2
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 229940066469 amlodipine 5 mg Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 2
- 229960004166 diltiazem Drugs 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002602 fendiline Drugs 0.000 description 2
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 2
- 229960000326 flunarizine Drugs 0.000 description 2
- 229960004427 isradipine Drugs 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 2
- 229960001783 nicardipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229960000227 nisoldipine Drugs 0.000 description 2
- 229960005425 nitrendipine Drugs 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 229940043102 valsartan and amlodipine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SVJMLYUFVDMUHP-XIFFEERXSA-N (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-XIFFEERXSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- NJXWZWXCHBNOOG-UHFFFAOYSA-N 3,3-diphenylpropyl(1-phenylethyl)azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C(C)[NH2+]CCC(C=1C=CC=CC=1)C1=CC=CC=C1 NJXWZWXCHBNOOG-UHFFFAOYSA-N 0.000 description 1
- OKCRIUNHEQSXFD-UHFFFAOYSA-N 5-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]-2-propan-2-yl-2-(3,4,5-trimethoxyphenyl)pentanenitrile;hydrochloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 OKCRIUNHEQSXFD-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 101150116411 AGTR2 gene Proteins 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- ZROUQTNYPCANTN-UHFFFAOYSA-N Tiapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC1(C=2C=C(OC)C(OC)=CC=2)S(=O)(=O)CCCS1(=O)=O ZROUQTNYPCANTN-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 description 1
- DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- PHFDAOXXIZOUIX-UHFFFAOYSA-N anipamil Chemical compound C=1C=CC(OC)=CC=1C(CCCCCCCCCCCC)(C#N)CCCN(C)CCC1=CC=CC(OC)=C1 PHFDAOXXIZOUIX-UHFFFAOYSA-N 0.000 description 1
- 229950011530 anipamil Drugs 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000002686 anti-diuretic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 229960005145 gallopamil hydrochloride Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004438 mibefradil Drugs 0.000 description 1
- 229960002439 mibefradil dihydrochloride Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 1
- 229950010800 niguldipine Drugs 0.000 description 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
- 229950000109 niludipine Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229960001989 prenylamine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- -1 ryosidine Chemical compound 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950003137 tiapamil Drugs 0.000 description 1
- 229940102034 valsartan 80 mg Drugs 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960000881 verapamil hydrochloride Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000003368 zona glomerulosa Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11389398A | 1998-07-10 | 1998-07-10 | |
| PCT/EP1999/004842 WO2000002543A2 (en) | 1998-07-10 | 1999-07-09 | Antihypersensitive combination of valsartan and calcium channel blocker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20010113D0 NO20010113D0 (no) | 2001-01-08 |
| NO20010113L NO20010113L (no) | 2001-03-09 |
| NO331802B1 true NO331802B1 (no) | 2012-04-10 |
Family
ID=22352165
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010113A NO331802B1 (no) | 1998-07-10 | 2001-01-08 | Antihypertensiv sammensetning av valsartan og kalsiumblokker |
| NO2012013C NO2012013I2 (no) | 1998-07-10 | 2012-07-03 | Antihypertensiv sammensetning av valsartan og kalsiumblokker |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2012013C NO2012013I2 (no) | 1998-07-10 | 2012-07-03 | Antihypertensiv sammensetning av valsartan og kalsiumblokker |
Country Status (32)
| Country | Link |
|---|---|
| EP (3) | EP2322174B1 (xx) |
| JP (1) | JP2002520274A (xx) |
| KR (2) | KR20040078140A (xx) |
| CN (2) | CN1733307A (xx) |
| AT (1) | ATE371448T1 (xx) |
| AU (1) | AU753486B2 (xx) |
| BE (1) | BE2016C011I2 (xx) |
| BR (1) | BR9912021A (xx) |
| CA (2) | CA2678722C (xx) |
| CY (4) | CY1107779T1 (xx) |
| CZ (2) | CZ304359B6 (xx) |
| DE (2) | DE69936992T2 (xx) |
| DK (2) | DK2322174T3 (xx) |
| ES (2) | ES2552639T3 (xx) |
| FR (1) | FR16C0008I2 (xx) |
| HK (2) | HK1036758A1 (xx) |
| HU (1) | HU229383B1 (xx) |
| ID (1) | ID27664A (xx) |
| IL (3) | IL140665A0 (xx) |
| LU (2) | LU91358I2 (xx) |
| NL (2) | NL300290I2 (xx) |
| NO (2) | NO331802B1 (xx) |
| NZ (2) | NZ509260A (xx) |
| PL (1) | PL194604B1 (xx) |
| PT (2) | PT1096932E (xx) |
| RU (3) | RU2450813C2 (xx) |
| SG (1) | SG142116A1 (xx) |
| SI (2) | SI1096932T1 (xx) |
| SK (1) | SK285863B6 (xx) |
| TR (1) | TR200100062T2 (xx) |
| WO (1) | WO2000002543A2 (xx) |
| ZA (1) | ZA200100232B (xx) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2552639T3 (es) | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos |
| CN1636561A (zh) | 1998-12-23 | 2005-07-13 | 诺瓦提斯公司 | At－1受体拮抗剂在治疗与at－1受体增加有关的疾病中的应用 |
| HU226948B1 (en) * | 1999-04-28 | 2010-03-29 | Takeda Pharmaceutical | Use of angiotensin ii antagonist for prevention or therapy of progression of simplex retinopathy or preproliferating retinopathy |
| AU6019700A (en) * | 1999-07-21 | 2001-02-05 | Takeda Chemical Industries Ltd. | Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| WO2001062741A1 (en) | 2000-02-25 | 2001-08-30 | South Alabama Medical Science Foundation | Tetrahydronaphtalene derivatives and their use |
| AU2001235363A1 (en) * | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Mibefradil analogues and their use |
| SK14612002A3 (sk) * | 2000-04-12 | 2003-05-02 | Novartis Ag | Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie |
| DE10018401A1 (de) | 2000-04-13 | 2001-10-25 | Boehringer Ingelheim Pharma | Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen |
| AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
| US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| WO2002053147A1 (es) * | 2000-12-29 | 2002-07-11 | Osmotica Corp. | Composicion farmaceutica para el tratamiento de la enfermedad cerebrovascular cognitiva |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| AU2002363087A1 (en) * | 2001-10-18 | 2003-05-06 | Novartis Ag | Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
| EG24716A (en) | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040138306A1 (en) | 2002-07-25 | 2004-07-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| SE0300988D0 (sv) * | 2003-04-03 | 2003-04-03 | Astrazeneca Ab | New use |
| DK1628663T3 (da) | 2003-05-15 | 2010-03-08 | Roskamp Res Llc | Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose |
| TW200509909A (en) * | 2003-05-16 | 2005-03-16 | Novartis Ag | Use of organic compounds |
| US20050065094A1 (en) * | 2003-09-05 | 2005-03-24 | Boehringer Ingelheim International Gmbh | Use of telmisartan for the prevention and treatment of vascular headache |
| WO2005053687A1 (en) * | 2003-11-25 | 2005-06-16 | Novartis Ag | Combination of organic compounds |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| PT1874311E (pt) | 2005-04-15 | 2011-11-25 | Res & Innovation S P A | Método para prevenir, retardar ou reverter a deposição anómala de amilóide |
| GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| GB0520405D0 (en) * | 2005-10-07 | 2005-11-16 | Imp College Innovations Ltd | Biological agents and method |
| US20080261958A1 (en) * | 2005-11-08 | 2008-10-23 | Randy Lee Webb | Combination of Organic Compounds |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| TWI500422B (zh) | 2007-10-05 | 2015-09-21 | Alzheimer S Inst Of America Inc | 以（－）－尼代地平（ｎｉｌｖａｄｉｐｉｎｅ）對映異構物減低類澱粉沉積、類澱粉神經毒性及微神經膠細胞增生之方法 |
| CN101433536A (zh) * | 2007-11-12 | 2009-05-20 | 北京瑞康医药技术有限公司 | 含有烟酸氨氯地平和沙坦类药物的治疗组合物 |
| MX2010007281A (es) * | 2007-12-31 | 2010-10-05 | Lupin Ltd | Composiciones farmaceuticas de amlodipina y valsartan. |
| US20100137403A1 (en) * | 2008-07-10 | 2010-06-03 | Scott Malstrom | Method for enhancing cognition or inhibiting cognitive decline |
| SI2536396T1 (sl) | 2010-02-16 | 2017-01-31 | KRKA, tovarna zdravil, d.d.,Novo mesto | Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan |
| IT1400309B1 (it) | 2010-05-10 | 2013-05-24 | Menarini Int Operations Lu Sa | Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso. |
| EA024096B1 (ru) * | 2011-04-12 | 2016-08-31 | Борюн Фармасьютикал Ко., Лтд. | Противогипертоническая фармацевтическая композиция |
| EP2741736B1 (en) | 2011-08-12 | 2017-11-22 | Boehringer Ingelheim Vetmedica GmbH | Taste masked pharmaceutical composition |
| WO2013147137A1 (ja) * | 2012-03-30 | 2013-10-03 | 味の素株式会社 | 心不全の治療剤 |
| CZ2013783A3 (cs) | 2013-10-08 | 2015-04-15 | Zentiva, K. S | Stabilní farmaceutická kompozice obsahující amlodipin a valsartan |
| US20180071272A1 (en) * | 2014-10-23 | 2018-03-15 | The Trustees Of The University Of Pennsylvania | Novel chronotherapy based on circadian rhythms |
| RU2616213C2 (ru) * | 2015-07-10 | 2017-04-13 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) | Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте |
| ES2941769T3 (es) * | 2015-10-31 | 2023-05-25 | Io Therapeutics Inc | Tratamiento de trastornos del sistema nervioso utilizando combinaciones de agonistas de RXR y hormonas tiroideas |
| CN105287550A (zh) * | 2015-11-19 | 2016-02-03 | 哈尔滨圣吉药业股份有限公司 | 一种缬沙坦/非洛地平复方制剂及其制备方法 |
| US20230218583A1 (en) | 2020-04-17 | 2023-07-13 | Honeybrains, Llc | Compositions and methods for treating neuropsychiatric disorders |
| US20240299405A1 (en) * | 2020-05-28 | 2024-09-12 | Hangzhou Qian Biotechnology Ltd | Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4654372A (en) * | 1986-01-10 | 1987-03-31 | Warner-Lambert Company | Method for using verapamil for treating stroke |
| GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
| DE122007000050I1 (de) * | 1990-02-19 | 2007-11-08 | Novartis Ag | Acylverbindungen |
| US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
| NZ242724A (en) | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
| WO1993017682A1 (en) * | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| JP2571197B2 (ja) * | 1992-07-27 | 1997-01-16 | ファイザー インク． | アゲレノプシス・アペルタ由来のカルシウムチャンネル阻害ポリペプチド |
| US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
| US5721263A (en) * | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
| CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
| EP0634175B1 (de) * | 1993-07-15 | 2001-01-10 | F. Hoffmann-La Roche Ag | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
| CN1140409A (zh) * | 1994-02-08 | 1997-01-15 | 希巴-盖吉股份公司 | 血管紧张素ii拮抗剂对正常眼压性青光眼的治疗 |
| SK117996A3 (en) * | 1994-03-17 | 1997-03-05 | Ciba Geigy Ag | Pharmaceutical composition for treatment of diabetic nephropathy |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| ES2552639T3 (es) | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos |
-
1999
- 1999-07-09 ES ES10177093.1T patent/ES2552639T3/es not_active Expired - Lifetime
- 1999-07-09 AU AU50349/99A patent/AU753486B2/en not_active Expired
- 1999-07-09 CZ CZ2007-647A patent/CZ304359B6/cs not_active IP Right Cessation
- 1999-07-09 DK DK10177093.1T patent/DK2322174T3/en active
- 1999-07-09 SI SI9930996T patent/SI1096932T1/sl unknown
- 1999-07-09 JP JP2000558803A patent/JP2002520274A/ja active Pending
- 1999-07-09 RU RU2001102585/15A patent/RU2450813C2/ru active Protection Beyond IP Right Term
- 1999-07-09 TR TR2001/00062T patent/TR200100062T2/xx unknown
- 1999-07-09 SI SI9931078T patent/SI2322174T1/sl unknown
- 1999-07-09 AT AT99934647T patent/ATE371448T1/de active
- 1999-07-09 PL PL99345897A patent/PL194604B1/pl unknown
- 1999-07-09 CA CA2678722A patent/CA2678722C/en not_active Expired - Lifetime
- 1999-07-09 DK DK99934647T patent/DK1096932T3/da active
- 1999-07-09 DE DE69936992T patent/DE69936992T2/de not_active Expired - Lifetime
- 1999-07-09 SG SG200300082-5A patent/SG142116A1/en unknown
- 1999-07-09 EP EP10177093.1A patent/EP2322174B1/en not_active Revoked
- 1999-07-09 RU RU2001102585/15K patent/RU2243768C2/ru active
- 1999-07-09 ES ES99934647T patent/ES2289814T3/es not_active Expired - Lifetime
- 1999-07-09 WO PCT/EP1999/004842 patent/WO2000002543A2/en active IP Right Grant
- 1999-07-09 DE DE200712000055 patent/DE122007000055I1/de active Pending
- 1999-07-09 KR KR10-2004-7011566A patent/KR20040078140A/ko active Search and Examination
- 1999-07-09 CN CNA200510072738XA patent/CN1733307A/zh active Pending
- 1999-07-09 IL IL14066599A patent/IL140665A0/xx unknown
- 1999-07-09 KR KR1020017000323A patent/KR100550167B1/ko not_active IP Right Cessation
- 1999-07-09 CZ CZ20010087A patent/CZ299429B6/cs unknown
- 1999-07-09 SK SK31-2001A patent/SK285863B6/sk not_active IP Right Cessation
- 1999-07-09 HU HU0102828A patent/HU229383B1/hu active Protection Beyond IP Right Term
- 1999-07-09 NZ NZ509260A patent/NZ509260A/en not_active IP Right Cessation
- 1999-07-09 CA CA002336822A patent/CA2336822C/en not_active Expired - Lifetime
- 1999-07-09 EP EP99934647A patent/EP1096932B1/en not_active Revoked
- 1999-07-09 EP EP07105179A patent/EP1870098A3/en not_active Withdrawn
- 1999-07-09 BR BR9912021-6A patent/BR9912021A/pt not_active IP Right Cessation
- 1999-07-09 ID IDW20010051A patent/ID27664A/id unknown
- 1999-07-09 NZ NZ527598A patent/NZ527598A/xx not_active IP Right Cessation
- 1999-07-09 PT PT99934647T patent/PT1096932E/pt unknown
- 1999-07-09 CN CNB998097764A patent/CN1234357C/zh not_active Expired - Lifetime
- 1999-07-09 PT PT101770931T patent/PT2322174E/pt unknown
-
2001
- 2001-01-01 IL IL140665A patent/IL140665A/en unknown
- 2001-01-08 NO NO20010113A patent/NO331802B1/no not_active IP Right Cessation
- 2001-01-09 ZA ZA200100232A patent/ZA200100232B/en unknown
- 2001-11-02 HK HK01107697A patent/HK1036758A1/xx not_active IP Right Cessation
-
2007
- 2007-09-06 LU LU91358C patent/LU91358I2/fr unknown
- 2007-09-10 NL NL300290C patent/NL300290I2/nl unknown
- 2007-10-25 CY CY20071101384T patent/CY1107779T1/el unknown
- 2007-10-30 CY CY200700026C patent/CY2007026I2/el unknown
-
2011
- 2011-07-04 IL IL213926A patent/IL213926A0/en unknown
- 2011-07-11 HK HK11107161.5A patent/HK1152897A1/xx not_active IP Right Cessation
-
2012
- 2012-03-20 RU RU2012110522/15A patent/RU2012110522A/ru unknown
- 2012-07-03 NO NO2012013C patent/NO2012013I2/no unknown
-
2015
- 2015-10-06 CY CY20151100890T patent/CY1116770T1/el unknown
-
2016
- 2016-03-07 CY CY2016006C patent/CY2016006I1/el unknown
- 2016-03-07 NL NL300800C patent/NL300800I2/nl unknown
- 2016-03-07 FR FR16C0008C patent/FR16C0008I2/fr active Active
- 2016-03-07 LU LU92992C patent/LU92992I2/xx unknown
- 2016-03-07 BE BE2016C011C patent/BE2016C011I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO331802B1 (no) | Antihypertensiv sammensetning av valsartan og kalsiumblokker | |
| US6395728B2 (en) | Method of treatment and pharmaceutical composition | |
| US6204281B1 (en) | Method of treatment and pharmaceutical composition | |
| JP2005533023A5 (xx) | ||
| NO334002B1 (no) | Farmasøytisk sammensetning som omfatter renininhibitoren aliskiren, og minst ett ytterligere terapeutisk middel, anvendelse derav, samt kitt | |
| KR20110107877A (ko) | 유기 화합물의 조합제제 | |
| MXPA04011383A (es) | Composicion farmaceutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diuretico. | |
| WO2003035046A2 (en) | Salts formed of an at1-receptor antagonist and a cardiovascular agent | |
| AU2003200032B2 (en) | Method of treatment and pharmaceutical composition | |
| WO2006002983A1 (en) | Combination of organic compounds | |
| MXPA01000322A (en) | Method of treatment and pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: EXFORGE; NAT. REG. NO/DATE: EU/1/06/372/001-024/N 20070305; FIRST REG. NO/DATE: EU/1/06/372/001-024 20070116 Spc suppl protection certif: 2012013 Filing date: 20120703 |
|
| SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: EXFORGE; REG. NO/DATE: EU/1/06/372/001-024 20070305; FIRST REG.NO/DATE: EU/1/06/372/001-024 20061222 Spc suppl protection certif: 2012013 Filing date: 20120703 Extension date: 20211222 |
|
| MK1K | Patent expired | ||
| SPCX | Expiry of an spc |
Spc suppl protection certif: 2012013 |